国金证券股份有限公司 关于 舒泰神（北京）生物制药股份有限公司 2022 年度向特定对象发行股票 并在创业板上市 之 舒泰神（北京）生物制药股份有限公司 上市保荐书 舒泰神（北京）生物制药股份有限公司 上市保荐书 声 明 国金证券股份有限公司（以下简称"国金证券"、"本保荐机构"）及其保荐代 表人严强、吕雷根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司证券发行注册管理 办法》（以下简称"《注册管理办法》"）《证券发行上市保荐业务管理办法》（以 下简称"《保荐管理办法》"）等有关法律、法规和中国证券监督管理委员会（以 下简称"中国证监会"）的有关规定以及深圳证券交易所（以下简称"深交所"）的 有关业务规则，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律 规范出具本上市保荐书，并保证上市保荐书的真实、准确、完整。 如无特别说明，本上市保荐书中所涉简称与《舒泰神（北京）生物制药股份 有限公司 2022 年度向特定对象发行股票募集说明书》一致。 上市保荐书 保荐机构（主承销商） （成都市青羊区东城根上街 95 号） 二〇二三年八月 舒泰神 ...

舒泰神（北京）生物制药股份有限公司 关于收到《关于舒泰神(北京)生物制药股份有限公司申请向特定对象发行股票 的审核中心意见告知函》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司""舒泰神"）于 2023 年 08 月 09 日收到深圳证券交易所（以下简称"深交所"）上市审核中心出具的 《关于舒泰神(北京)生物制药股份有限公司申请向特定对象发行股票的审核中 心意见告知函》（以下简称"告知函"）。 深交所发行上市审核机构对公司向特定对象发行股票的申请文件进行了审 核，认为公司符合发行条件、上市条件和信息披露要求，后续深交所将按规定报 中国证券监督管理委员会（以下简称"中国证监会"）履行相关注册程序。 证券代码：300204 证券简称：舒泰神 公告编号：2023-39-01 公司本次向特定对象发行股票事项尚需获得中国证监会同意注册的决定后 方可实施，最终能否获得中国证监会作出同意注册的决定及其时间尚存在不确定 性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注意 投资风险。 特此公告 舒泰 ...

Financial Performance - The company's revenue for Q1 2023 was ¥65,017,235.12, a decrease of 47.29% compared to ¥123,340,760.08 in the same period last year[3] - The net loss attributable to shareholders was ¥48,725,047.50, representing a 99.62% increase in loss from ¥24,409,475.07 year-on-year[3] - The net cash flow from operating activities was -¥48,703,447.32, a decline of 31.99% compared to -¥36,899,357.21 in the previous year[3] - Operating income decreased by ¥58,323,524.96, a drop of 47.29%, mainly due to adverse effects from centralized procurement policies[8] - Sales expenses decreased by ¥19,975,150.89, a reduction of 40.10%, attributed to lower sales revenue[8] - Total operating revenue for Q1 2023 was ¥65,017,235.12, a decrease of 47.3% compared to ¥123,340,760.08 in the same period last year[28] - Total operating costs for Q1 2023 were ¥112,694,083.52, down 24.7% from ¥149,627,134.34 year-over-year[28] - Net loss for Q1 2023 was ¥48,725,047.50, compared to a net loss of ¥24,409,475.07 in Q1 2022, representing a 99.5% increase in losses[29] - The company reported a comprehensive loss of ¥78,828,739.97 for Q1 2023, compared to a comprehensive loss of ¥73,058,069.38 in Q1 2022[30] - Basic and diluted earnings per share for Q1 2023 were both -¥0.10, compared to -¥0.05 in the same quarter last year[30] Assets and Liabilities - Total assets decreased by 7.71% to ¥1,540,576,544.83 from ¥1,669,315,254.73 at the end of the previous year[4] - The company's current assets totaled CNY 447,292,083.04, down from CNY 529,058,099.35 at the start of the year, indicating a reduction of approximately 15.5%[25] - The company's cash and cash equivalents were CNY 212,005,194.21, compared to CNY 264,987,760.35 at the beginning of the year, reflecting a decrease of about 20%[25] - Total liabilities amounted to ¥265,242,801.64, a decrease from ¥315,452,471.57 year-over-year[29] - Total equity attributable to shareholders was ¥1,275,333,743.19, down from ¥1,353,862,783.16 in the previous year[29] - The company reported a total non-current asset value of CNY 1,093,284,461.79, down from CNY 1,140,257,155.38 at the beginning of the year[26] Cash Flow - Cash flow from operating activities showed a net outflow of ¥48,703,447.32, worsening from a net outflow of ¥36,899,357.21 in Q1 2022[31] - Cash inflow from investment activities was ¥13,541,351.26, significantly lower than ¥102,616,156.22 in the previous year[31] - The net cash flow from investment activities was 8,184,269.95 CNY, compared to 55,899,099.38 CNY in the same period last year[32] - The net cash flow from financing activities was -12,404,750.94 CNY, indicating a significant outflow compared to -611,439.43 CNY in the previous year[32] - The cash outflow from investment activities totaled 5,357,081.31 CNY in Q1 2023, compared to 46,717,056.84 CNY in the same quarter last year[32] - The cash inflow from financing activities was 688,720.00 CNY, with cash outflow totaling 13,093,470.94 CNY in Q1 2023[32] - The net increase in cash and cash equivalents for Q1 2023 was -52,982,566.14 CNY, contrasting with an increase of 18,306,773.64 CNY in the previous year[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,084[13] - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., holds 36.30% of shares, totaling 172,532,363 shares[13] - The second-largest shareholder, Xiangtang Group Co., Ltd., holds 9.06% of shares, totaling 43,082,186 shares, with 41,472,708 shares pledged[13] - The total number of restricted shares held by executives at the end of the period is 5,798,871 shares[15] - The company’s major shareholders include various asset management plans and individual investors, indicating a diverse ownership structure[14] Clinical Trials and Product Development - The company has completed the first patient dosing for the Phase II clinical trial of STSP-0601 for hemophilia A or B patients[17] - The Phase I clinical trial results for STSA-1002 indicate good safety and tolerability, with a significant reduction in C5a levels post-administration[18] - The company reported a trend of improved healing rates for diabetic foot ulcers when using Su Taisheng in conjunction with standard treatment[17] - The company has received approval for multiple new indications for its products, enhancing its clinical pipeline[17][18] - The company is actively expanding its clinical research and product development efforts, focusing on innovative therapies[17][18] - The company announced the initiation of the Ib/II clinical trial for the gene drug "STSG-0002 injection" targeting chronic hepatitis B virus infection, with the trial focusing on safety and efficacy[19] - The company received approval from the National Medical Products Administration for the clinical trial of "STSA-1002 injection" for acute respiratory distress syndrome (ARDS)[20] - The company's subsidiary InflaRx obtained FDA Emergency Use Authorization (EUA) for the drug Gohibic (Vilobelimab) to treat COVID-19 in hospitalized adults[20] Compliance and Regulatory - The company passed the GMP compliance inspection for its oral solution production line, confirming adherence to the 2020 revised Drug Production Quality Management Standards[21] - The company is in the process of issuing shares to specific investors, with the application accepted by the Shenzhen Stock Exchange[19] Miscellaneous - The company reported a negative impact of -58,637.83 CNY from exchange rate fluctuations on cash and cash equivalents[32] - The company’s first-quarter report for 2023 was not audited[33]

舒泰神（北京）生物制药股份有限公司 向特定对象发行股票的审核问询函的回复 天衡专字(2023) 00831 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mcf.mor.cn）"进行营" "进行" 舒泰神(北京)生物制药股份有限公司 向特定对象发行股票的审核问询函的回复 天衡专字(2023) 00831 号 深圳证券交易所: 根据贵所于 2023年3月 16 日出具的《关于舒泰神(北京)生物制药股份 有限公司申请向特定对象发行股票的审核间询函》(审核函(2023)020046号) 所列的问题,天衡会计师事务所(特殊普通合伙)(以下简称"本所"或"申报 会计师")作为舒泰神(北京)生物制药股份有限公司(以下简称"舒泰神"、"公 司"、"发行人"或"申请人")向特定对象发行股票的申报会计师,我们对反馈意见 中需申报会计师核查的相关问题进行了认真核查,现将有关情况汇报说明如下: 一、申报材料显示,本次发行拟募集资金总额不超过58,000万元,全部用 于创新药物研发项目,具体包括 BDB-001 注射液、注射用 STSP-0601、 STSA-1002和STSA-1005联合用药三 ...

舒泰神(北京)生物制药股份有限公司 向特定对象发行股票的审核问询函的回复 天衡专字(2023) 00509 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ 报告编码:苏2374 舒泰神(北京)生物制药股份有限公司 向特定对象发行股票的审核问询函的回复 天衡专字(2023)00509 号 深圳证券交易所: 根据贵所于 2023年3月16日出具的《关于舒泰神(北京)生物制药股份 有限公司申请向特定对象发行股票的审核间询函》(审核函(2023)020046号) 所列的问题,天衡会计师事务所(特殊普通合伙)(以下简称"本所"或"申报 会计师")作为舒泰神(北京)生物制药股份有限公司(以下简称"舒泰神"、"公 司"、"发行人"或"申请人")向特定对象发行股票的申报会计师,我们对反馈意见 中儒申报会计师核查的相关问题进行了认真核查,现将有关情况汇报说明如下: 一、申报材料显示,本次发行拟募集资金总额不超过 58,000万元. 全部用 于创新药物研发项目,具体包括 BDB-001 注射液、注射用 STSP-0601、 STSA-1002和STSA-1005联合用药 ...

Financial Performance - The company achieved a total sales revenue of 549 million yuan in 2022, representing a decrease of 6.04% compared to the previous year[5]. - The company's operating revenue for 2022 was ¥548,988,617.75, a decrease of 6.04% compared to ¥584,291,440.90 in 2021[28]. - The net profit attributable to shareholders for 2022 was -¥197,008,085.75, representing a decline of 43.38% from -¥137,400,196.24 in 2021[28]. - The basic earnings per share for 2022 was -¥0.41, down 41.38% from -¥0.29 in 2021[29]. - The total revenue for the company in 2022 was approximately ¥548.99 million, representing a decrease of 6.04% compared to ¥584.29 million in 2021[73]. - The main product, Su Tai Sheng, generated sales revenue of ¥174.02 million, accounting for 31.70% of total revenue, with a year-on-year decline of 3.73%[67]. - The company's other main product, Shu Tai Qing, achieved sales revenue of ¥365 million, making up 66.43% of total revenue, which is an 8.47% decrease from the previous year[67]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[179]. - The company reported a net profit of 416 million RMB, representing a growth of 156.49% year-over-year[173]. Research and Development - Research and development expenses for the year amounted to 363 million yuan, which is an increase of 0.08% year-on-year[5]. - The company plans to sustain a high level of R&D investment in the near future due to the ongoing progress of its research projects[6]. - The company’s R&D pipeline includes protein drugs, gene therapy/cell therapy drugs, and chemical drugs, targeting unmet clinical needs in infectious diseases, autoimmune diseases, and neurological disorders[42]. - The company has multiple I class innovative biopharmaceuticals in clinical trial stages, including BDB-001, STSA-1002, STSA-1005, STSP-0601, and STSG-0002, with ongoing research in areas such as neurological diseases, infectious diseases, and autoimmune diseases[52]. - The company has developed a leading new drug R&D technology platform, including various advanced screening and production systems, to support its innovative drug development[58]. - The company is focusing on accelerating the progress of its R&D projects, particularly those in Phase I and II/III clinical trials, to advance them to the next stages[120]. - The company has allocated 60 million RMB for research and development in the upcoming fiscal year, a 15% increase from 2022[175]. Market Strategy and Expansion - The company emphasizes a strategy of innovation-driven development and aims to enhance its marketing capabilities to support ongoing research projects[6]. - The company is exploring new project launches through acquisitions and collaborative development to expand its research pipeline[7]. - The company plans to expand its market presence in the constipation-related market based on its success in the bowel cleansing sector[41]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[174]. - The company is exploring partnerships with international firms to broaden its distribution network, aiming for a 25% increase in international sales[179]. - The company is actively involved in technology development, transfer, and consulting services, which are key components of its business model[118]. Governance and Compliance - The company has established a comprehensive governance structure to ensure effective decision-making and supervision[130]. - The company emphasizes strict compliance with information disclosure regulations, designating the chairman as the primary responsible person for information disclosure[138]. - The board of directors consists of seven members, including three independent directors, and all directors actively participated in relevant training to enhance their capabilities[135]. - The company has established specialized committees under the board, including the Strategy, Nomination, Audit, and Compensation Committees, to enhance governance and decision-making[162]. - The company has maintained effective communication with investors through various channels, enhancing investor relations management[138]. Financial Management - The company has implemented cost-control measures that are expected to reduce operational expenses by 5% in the next year[174]. - The total remuneration paid to the current directors, supervisors, and senior management in 2022 amounted to RMB 10.2585 million and USD 150,000[190]. - The company has committed to improving its internal control systems and management capabilities to adapt to its expanding operational scale[125]. - The company has ensured timely, accurate, and complete disclosure of the use of raised funds, with no violations in fund management and disclosure[104]. Challenges and Risks - The company reported a net profit of negative value for the reporting period, indicating ongoing short-term performance pressure[5]. - The pharmaceutical industry faces challenges from external policies such as centralized procurement and medical reform, impacting production and sales[6]. - The company acknowledges the inherent risks in drug development, including high investment and long development cycles, which may affect profitability[7]. - The company faces risks related to the development and market acceptance of innovative drugs, which may impact its business and financial status[122]. - The company is addressing the risk of talent shortages by improving its human resource management system and establishing an employee equity incentive plan[123].

证券代码：300204 证券简称：舒泰神 公告编号：2023-11-16 舒泰神（北京）生物制药股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）已于 2023 年 03 月 21 日披露了公司 2022 年年度报告。为便于广大投资者更深入、全面地了解公 司发展战略、生产经营等情况，公司定于 2023 年 04 月 07 日（星期五）下午 15:00 －17:00 举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式 举行，投资者可登录全景网"投资者关系互动平台"（http://rs.p5w.net）参与本次 年度业绩说明会。 出席本次年度业绩网上说明会的人员有：董事长周志文先生、总经理王超先 生、董事会秘书兼副总经理于茂荣先生、独立董事孙英女士。 欢迎广大投资者积极参与。 特此公告 舒泰神（北京）生物制药股份有限公司 董事会 2023 年 03 月 20 日 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 ...

Group 1: Company Overview - Staidson (Beijing) Biopharmaceutical Co., Ltd. is identified with the stock code 300204 and the abbreviation Shutaishen [1] Group 2: Investor Relations Activity - The investor relations activity recorded was a specific object investigation conducted on October 24, 2014 [2] - Participating units included Huachuang Securities and Liuhe Investment [2] - The meeting was held in the company conference room, hosted by Marina [2] Group 3: Main Content of the Activity - The main topics discussed included sales situation, product status, and investment acquisition [2]